Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

58°
- Benton, AR (72018)
  Today
  
  Showers early, then cloudy in the afternoon. High 71F. Winds ESE at 5 to 10 mph. Chance of rain 50%..
  
  Tonight
  
  Cloudy. A stray shower or thunderstorm is possible. Low 64F. Winds S at 5 to 10 mph.
  
  Updated: November 17, 2025 @ 8:11 am
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

25.46 +0.05 (+0.20%)

Streaming Delayed Price Updated: 9:37 AM EST, Nov 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

June 18, 2025

EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:PFE),(NASDAQ:COLL),(NYSE:TEVA),(NYSE:EBS) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 16, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

How Do Investors Really Feel About Teva Pharmaceutical Indus? ↗

June 05, 2025

Via Benzinga

Where Teva Pharmaceutical Indus Stands With Analysts ↗

May 28, 2025

Via Benzinga

Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030

June 18, 2025

From FN Media Group LLC

Via GlobeNewswire

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters ↗

June 16, 2025

Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years.

Via The Motley Fool

Topics Artificial Intelligence Economy

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? ↗

June 06, 2025

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook.

Via Benzinga

9 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2025

Via Benzinga

Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer

June 03, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement

June 03, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025

May 30, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with

May 30, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030 ↗

May 29, 2025

Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base.

Via Benzinga

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

May 29, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead ↗

May 28, 2025

Duquesne Family Office's chief dumped his entire stake in one of Wall Street's premier stock-split stocks and has continued to load up on a super-cheap drug company for a third straight quarter.

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA

May 27, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June

May 27, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Why Is Teva Stock Trading Higher On Tuesday? ↗

May 27, 2025

Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.

Via Benzinga

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

May 27, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes

May 22, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

May 20, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

May 20, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

May 19, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes

May 19, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy

May 15, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today ↗

May 12, 2025

Via The Motley Fool

Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday ↗

May 12, 2025

Via Benzinga

This Wayfair Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

May 12, 2025

Via Benzinga

Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

May 12, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Why Teva Pharmaceutical Stock Is Soaring Today ↗

May 07, 2025

Via The Motley Fool

Topics Earnings Stocks

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

Sections

Services

Follow Us